Sugi Predict

Sugi Predict / Targets / SIRT3

SIRT3

NAD-dependent protein deacetylase sirtuin-3, mitochondrial · Q9NTG7 · SIRT3 on Sugi Atlas →

38,511 patent compounds predicted against SIRT3, 22,182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL460244 SCHEMBL460244 0.41 12/20
SCHEMBL671485 SCHEMBL671485 0.65 11/20
SCHEMBL388531 SCHEMBL388531 0.56 10/20
Amiodarone Amiodarone (SCHEMBL297474) 0.63 9/20
SCHEMBL203978 SCHEMBL203978 0.53 9/20
Amiodarone Amiodarone (SCHEMBL16284) 1.00 7/20
Amiodarone Amiodarone (SCHEMBL41348) 0.98 7/20
SCHEMBL458871 SCHEMBL458871 0.47 7/20
SCHEMBL520949 SCHEMBL520949 0.47 7/20
SCHEMBL757490 SCHEMBL757490 0.44 7/20
SCHEMBL732234 SCHEMBL732234 0.61 6/20
SCHEMBL750042 SCHEMBL750042 0.61 6/20
Caprolactam Caprolactam (SCHEMBL161418) 0.37 6/20
Bucromarone Bucromarone (SCHEMBL124678) 0.56 5/20
SCHEMBL163690 SCHEMBL163690 0.38 5/20
SCHEMBL209612 SCHEMBL209612 0.62 4/20
SCHEMBL150166 SCHEMBL150166 0.58 4/20
SCHEMBL254960 SCHEMBL254960 0.53 4/20
SCHEMBL133032 SCHEMBL133032 0.50 4/20
SCHEMBL57020 SCHEMBL57020 0.48 4/20

Clinical trials — most relevant to SIRT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression PHASE2/PHASE3NOT_YET_RECRUITING
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age PHASE2COMPLETED
Oral Nitrite for Older Heart Failure Patients PHASE2COMPLETED
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension PHASE2NOT_YET_RECRUITING
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy PHASE2COMPLETED
Y-90 SIRT for Unresectable HCC Larger Than 7cm PHASE2RECRUITING
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals PHASE2RECRUITING
The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care PHASE2COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors PHASE1RECRUITING
Project SIRT6 Activator nanRECRUITING
Sirtuin1 in COVID19 Patients nanUNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery nanNOT_YET_RECRUITING
How Sirtuin Levels Change During Behçet Disease nanUNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Inflammation in COPD and the Effect of Nicotinamide Riboside nanCOMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Mitochondria Oxidative Stress and Vascular Health Study nanCOMPLETED
Short Interval Resveratrol Trial in Cardiovascular Surgery nanACTIVE_NOT_RECRUITING
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis nanUNKNOWN
Nicotinamide Riboside Clinical Trial for GWI nanRECRUITING
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity nanCOMPLETED
Role of Fasted Exercise on Improving Cardiometabolic Health nanUNKNOWN
NR Supplementation and Exercise nanCOMPLETED
Nicotinamide Riboside in Ulcerative Colitis nanRECRUITING
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients nanUNKNOWN
Inflammatory Axis and Sirtuins' in Overweight Pre-diabetics Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SIRT3 binder may also engage these)

ProteinNameSimilarity
Q8R104 — 0.987 Q8R104 →
Q4R834 — 0.985 Q4R834 →
Q8VDQ8 — 0.984 Q8VDQ8 →
F7EZ75 — 0.983 F7EZ75 →
Q3ZBQ0 — 0.982 Q3ZBQ0 →
Q8BKJ9 — 0.981 Q8BKJ9 →
Q5RBF1 — 0.980 Q5RBF1 →
Q0P595 — 0.980 Q0P595 →
Q5AW69 — 0.979 Q5AW69 →
SIRT2 NAD-dependent protein deacetylase sirtuin-2 0.978 landscape →
B2RZ55 — 0.978 B2RZ55 →
Q6L534 — 0.978 Q6L534 →
Q5ZHX9 — 0.977 Q5ZHX9 →
SIRT7 NAD-dependent protein deacetylase sirtuin-7 0.977 landscape →
P52785 — 0.977 P52785 →
Q68FX9 — 0.976 Q68FX9 →
Q5R6G3 — 0.976 Q5R6G3 →
Q94AQ6 — 0.976 Q94AQ6 →
Q9HCE1 — 0.976 Q9HCE1 →
Q5R9R9 — 0.975 Q5R9R9 →
F7DKV7 — 0.975 F7DKV7 →
P38935 — 0.975 P38935 →
Q2QMG2 — 0.975 Q2QMG2 →
Q148I5 — 0.975 Q148I5 →
Q8R4H7 — 0.975 Q8R4H7 →
Q8R216 — 0.975 Q8R216 →
Q9I7I7 — 0.975 Q9I7I7 →
Q42606 — 0.975 Q42606 →
Q5RJQ4 — 0.975 Q5RJQ4 →
Q9ZQV6 — 0.975 Q9ZQV6 →